You are here

Novel Approaches for Detection of and Protection from Emerging Viral Pandemics

Description:

TECHNOLOGY AREA(S): Bio Medical

OBJECTIVE: Develop and promote novel approaches for the detection, identification, and differentiation of viral pathogens, contamination prevention, and protection from viral infections, such as COVID-19.

DESCRIPTION: Defense Logistics Agency (DLA) Research and Development topics of interest are research focused on complex catastrophic pandemic events, such as COVID-19.This requirement consists of providing materials that block transmission of viral pathogens on various surfaces such as clothing, Meals-Ready-To-Eat (MREs), bottled water, parts, and other mediums of transmission of viral pathogens.Solutions need to be easy to use, rapidly deployable, with low logistics burden for military logisticians, clinics, medical treatment facilities, and forward deployed military and civilian personnel.

PHASE I: Not Required.The vendor must demonstrate Proof of Concept via a technical volume not to exceed 20 pages.This volume is included as part of the Phase II Technical volume (Volume 2)FEASIBILITY DOCUMENTATION: Offerors interested in participating in Direct to Phase II must include in their response to this topic Phase I feasibility documentation that substantiates the scientific and technical merit and Phase I feasibility described in Phase I above has been met (i.e. the small business must have performed Phase I-type research and development related to the topic, but from non-SBIR funding sources) and describe the potential commercialization applications.The documentation provided must validate that the proposer has completed development of technology as stated in Phase I above.Documentation should include all relevant information including, but not limited to: technical reports, test data, prototype designs/models, and performance goals/results.Work submitted within the feasibility documentation must have been substantially performed by the offeror and/or the principal investigator (PI).

PHASE II: Based on the results of the vendors Proof of Concept, and in coordination with DLA and industry manufacturers the Phase II expectation is to develop a prototype solution.This solution must be easy to use with a minimal burden on logistics, which effectively prevents escalation of the transmission of viral pathogens through contact, particularly from contaminated surfaces.The envisioned platform would cut response time significantly in order to stay within the window of relevance for containing contamination, preventing infection, and mitigating an outbreak.

PHASE III: Dual Use Applications: At this point, no specific funding is associated with Phase III.Progress made in Phase I and Phase II should result in the use of U.S. and European Union domestic health care markets for in vitro diagnostics and prophylactic uses.COMMERCIALIZATION:The manufacturer will pursue commercialization of various identification of, protection, and mitigation from viral pathogens, such as COVID-19 and develop potential commercial sales of manufactured chemical materials.

KEYWORDS: Covid-19, infections disease, in vitro diagnostic, point of care, biological warfare agent, biomarkers, anti-viral, MERS, SARS, coronavirus

US Flag An Official Website of the United States Government